finanzen.net
19.04.2019 22:56
Bewerten
(0)

CORT MAY 13th DEADLINE ALERT: Rosen Law Firm Reminds Corcept Therapeutics Incorporated Investors of Important Deadline in Securities Class Action Lawsuit

DRUCKEN

NEW YORK, April 19, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Corcept Therapeutics Incorporated from August 2, 2017 through February 5, 2019, inclusive (the "Class Period") of the important May 13, 2019 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Corcept investors under the federal securities laws.

Rosen Law Firm, P.A. Logo

To join the Corcept class action, go to https://www.rosenlegal.com/cases-register-1536.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Corcept had improperly paid doctors to promote its drug, Korlym; (2) Corcept aggressively promoted Korlym for off-label uses; (3) Corcept's sole specialty pharmacy was a related party; (4) Corcept artificially inflated its revenue and sales using illicit sales practices through a related party; (5) such practices were reasonably likely to lead to regulatory scrutiny; and (6) as a result, defendants' positive statements about Corcept's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to https://www.rosenlegal.com/cases-register-1536.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 34th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      cases@rosenlegal.com
      www.rosenlegal.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cort-may-13th-deadline-alert-rosen-law-firm-reminds-corcept-therapeutics-incorporated-investors-of-important-deadline-in-securities-class-action-lawsuit-300835272.html

SOURCE Rosen Law Firm, P.A.

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX schließt klar im Minus -- US-Börsen rot -- Tesla-Aktie nach Analyse unter Druck -- Infineon setzt wohl Chip-Lieferungen an Huawei aus - Unternehmen dementiert -- Wirecard, Deutsche Bank im Fokus

Halbleiterwerte leiden unter Sorge um Huawei-Lieferbeziehungen. HSBC-Analyse setzt Apple-Aktie unter Druck. Bitcoin hält sich nach Kursturbulenzen bei 8.000 US-Dollar. MorphoSys: Zeitplan für erstes eigenes Medikament bleibt unverändert. Pfeiffer Vacuum und Mehrheitsaktionär Busch kooperieren.

Die 5 beliebtesten Top-Rankings

Diese Aktien hat Warren Buffett im Depot
Die Änderungen unter den Top-Positionen
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
In diesen Berufen bekommt man das höchste Gehalt
Mit welchem Beruf kommt man am ehesten an die Spitze?
Städte für Millionäre
Hier fühlen sich die Vermögenden am wohlsten
In diesen Ländern ist Netflix am billigsten
Wo zahlen Abonnenten am wenigsten?
mehr Top Rankings

Umfrage

Die rechtspopulistische FPÖ in Österreich hat für einen Skandal gesorgt. Wie glauben Sie wird sich das auf die Europawahlen auswirken?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Huawei TechnologiesHWEI11
Deutsche Bank AG514000
TeslaA1CX3T
Daimler AG710000
CommerzbankCBK100
Apple Inc.865985
Amazon906866
BayerBAY001
BASFBASF11
Infineon AG623100
NEL ASAA0B733
Deutsche Telekom AG555750
Allianz840400
BMW AG519000